Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
49 hedge funds and large institutions have $94M invested in Genocea Biosciences, Inc. in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 7 closing their positions.
1,055% more call options, than puts
Call options by funds: $127K | Put options by funds: $11K
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
47% more capital invested
Capital invested by funds: $64M → $94M (+$30M)
4% more funds holding
Funds holding: 47 → 49 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.41M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$484K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$376K |
| 4 |
JP Morgan Chase
New York
|
+$174K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.02M |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$865K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$244K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$225K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$107K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Goldman Sachs
New York
| – | -$63K | -1,925 | Closed |
|
|
IA
52
IFP Advisors
Tampa,
Florida
| – | -$21K | -625 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$15K | -468 | Closed |
|
54
Simplex Trading
Chicago,
Illinois
| – | -$12.3K | -314 | Closed |
|
55
Creative Planning
Overland Park,
Kansas
| – | -$8K | -250 | Closed |
|
GNCA Hedge Fund Activity: Q1 2017 in Review
49 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2017, worth a combined $94M — up 47% from $64M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GNCA positions and 7 closed out — a net gain of 6 holders — while 15 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $1.41M. The largest seller was Deerfield Management, cutting an estimated $1.02M.
- 49 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2017, up from 47 in Q4 2016.
- Funds reported $94M of Genocea Biosciences, Inc. stock for Q1 2017, up 47% quarter-over-quarter.
- 13 funds opened new Genocea Biosciences, Inc. positions in Q1 2017 and 7 closed out, a net change of +6 holders.
- The largest Genocea Biosciences, Inc. buyer in Q1 2017 was BlackRock, an estimated $1.41M added.
- The largest Genocea Biosciences, Inc. seller in Q1 2017 was Deerfield Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2017.